Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of oxaliplatin when given
together with irinotecan in treating young patients with refractory solid tumors or
lymphomas. Drugs used in chemotherapy, such as oxaliplatin and irinotecan, work in different
ways to stop the growth of cancer cells, either by killing the cells or by stopping them from
dividing. Oxaliplatin may help irinotecan kill more cancer cells by making cancer cells more
sensitive to the drug. Giving oxaliplatin together with irinotecan may kill more cancer
cells.